Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis

Dermatol Ther. 2022 May;35(5):e15421. doi: 10.1111/dth.15421. Epub 2022 Mar 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / pathology
  • Humans
  • Nitriles
  • Primary Myelofibrosis* / drug therapy
  • Pyrazoles
  • Pyrimidines
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • cemiplimab
  • ruxolitinib